Regeneron Pharmaceuticals (REGN) Other financing activities (2013 - 2025)

Regeneron Pharmaceuticals' (REGN) quarterly Other financing activities came in at -$10.3 million in Q1 2025, up 69.16% quarter-over-quarter from -$33.4 million in Q3 2024.

Regeneron Pharmaceuticals (REGN) Other financing activities (2013 - 2025) Analysis & Trends

Regeneron Pharmaceuticals' Other financing activities history runs 6 years deep, the most recent figure standing at -$10.3 million for Q1 2025.

  • On a quarterly basis, Other financing activities changed N/A year-over-year to -$10.3 million in Q1 2025; TTM through Dec 2025 was -$10.3 million, a 69.16% increase from a year earlier, with the FY2025 full-year figure at -$10.3 million, up 69.16% from the prior year.
  • Other financing activities climbed to -$10.3 million in Q1 2025 per REGN's latest filing, from -$33.4 million in the prior quarter.
  • Across five years, Other financing activities topped out at -$10.3 million in Q1 2025 and bottomed at -$33.4 million in Q3 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn
7 Belite Bio 61.40 Bn 61.40 Bn -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn
9 Revolution Medicines 37.37 Bn 37.37 Bn -
10 Alnylam Pharmaceuticals 36.08 Bn 33.07 Bn 959.66 Mn

Historic Data

Download Data
DateValue
Mar 31, 2025 -10.30 Mn
Mar 31, 2025 -10.30 Mn
Sep 30, 2024 -33.40 Mn
Sep 30, 2024 -33.40 Mn
Sep 30, 2016 8.60 Mn
Sep 30, 2016 8.60 Mn
Jun 30, 2016 39.80 Mn
Jun 30, 2016 39.80 Mn
Mar 31, 2016 15.60 Mn
Mar 31, 2016 15.60 Mn
Dec 31, 2015 99.77 Mn
Dec 31, 2015 99.77 Mn
Sep 30, 2015 56.83 Mn
Sep 30, 2015 56.83 Mn
Jun 30, 2015 78.92 Mn
Jun 30, 2015 78.92 Mn
Mar 31, 2015 169.79 Mn
Mar 31, 2015 169.79 Mn
Dec 31, 2014 105.13 Mn
Dec 31, 2014 105.13 Mn